Stocktoria
Kura Oncology, Inc. KURA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-11-05
Kura Oncology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — |
| R&D expense | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M |
| SG&A expense | $120.0M | $77.1M | $50.6M | — | — |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — |
| Interest expense | — | — | $1.5M | $229,000 | $414,000 |
| Income tax | $297,000 | $2.0M | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M |
| EPS (diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M |
| Cash & equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M |
| Inventory | $413,000 | $0 | — | — | — |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M |
| Shareholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
Source: SEC EDGAR filings · CIK 0001422143 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.